Immunology and Immune Therapies for Cancer
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 31 December 2025 | Viewed by 14
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer immunology has rapidly evolved from a foundational research area into a cornerstone of modern oncology, with immune-based therapies transforming the clinical landscape for various malignancies. This Special Issue, “Immunology and Immune Therapies for Cancer”, seeks to highlight recent advances and emerging frontiers in our understanding of tumor–immune interactions and the development of novel immunotherapeutic strategies.
We welcome original research articles, comprehensive reviews, and insightful perspectives that explore key topics including tumor immune microenvironment dynamics, immune evasion mechanisms, cancer vaccines, checkpoint inhibitors, adoptive cell therapies (such as CAR-T and TCR-engineered cells), and the role of innate and adaptive immunity in cancer progression and treatment resistance. Submissions addressing combinatorial therapies, biomarker discovery, and translational approaches that bridge the bench-to-bedside divide are particularly encouraged.
By bringing together cutting-edge research and critical analyses, this Special Issue aims to foster a deeper understanding of the immunological principles underpinning cancer therapy and inspire the development of next-generation immune interventions. We look forward to your valuable contributions to this timely and impactful collection.
Dr. Mei Yu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- tumor microenvironment
- CAR-T cells
- immune checkpoint inhibitors
- immune surveillance
- cancer vaccines
- immuno-oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
